TY - JOUR
T1 - Perspectives in Immunotherapy
T2 - meeting report from the Immunotherapy Bridge, December 1st–2nd, 2021
AU - Ascierto, Paolo A.
AU - Avallone, Antonio
AU - Bhardwaj, Nina
AU - Bifulco, Carlo
AU - Bracarda, Sergio
AU - Brody, Joshua D.
AU - Buonaguro, Luigi
AU - Demaria, Sandra
AU - Emens, Leisha A.
AU - Ferris, Robert L.
AU - Galon, Jérôme
AU - Khleif, Samir N.
AU - Klebanoff, Christopher A.
AU - Laskowski, Tamara
AU - Melero, Ignacio
AU - Paulos, Chrystal M.
AU - Pignata, Sandro
AU - Ruella, Marco
AU - Svane, Inge Marie
AU - Taube, Janis M.
AU - Fox, Bernard A.
AU - Hwu, Patrick
AU - Puzanov, Igor
N1 - Publisher Copyright:
© 2022, The Author(s).
PY - 2022/12
Y1 - 2022/12
N2 - Over the past decade, immunotherapy has become an increasingly fundamental modality in the treatment of cancer. The positive impact of immune checkpoint inhibition, especially anti-programmed death (PD)-1/PD-ligand (L)1 blockade, in patients with different cancers has focused attention on the potential for other immunotherapeutic approaches. These include inhibitors of additional immune checkpoints, adoptive cell transfer (ACT), and therapeutic vaccines. Patients with advanced cancers who previously had limited treatment options available may now benefit from immunotherapies that can offer durable responses and improved survival outcomes. However, despite this, a significant proportion of patients fail to respond to immunotherapy, especially those with less immunoresponsive cancer types, and there remains a need for new treatment strategies. The virtual Immunotherapy Bridge (December 1st–2nd, 2021), organized by the Fondazione Melanoma Onlus, Naples, Italy in collaboration with the Society for Immunotherapy of Cancer addressed several areas of current research in immunotherapy, including lessons learned from cell therapies, drivers of immune response, and trends in immunotherapy across different cancers, and these are summarised here.
AB - Over the past decade, immunotherapy has become an increasingly fundamental modality in the treatment of cancer. The positive impact of immune checkpoint inhibition, especially anti-programmed death (PD)-1/PD-ligand (L)1 blockade, in patients with different cancers has focused attention on the potential for other immunotherapeutic approaches. These include inhibitors of additional immune checkpoints, adoptive cell transfer (ACT), and therapeutic vaccines. Patients with advanced cancers who previously had limited treatment options available may now benefit from immunotherapies that can offer durable responses and improved survival outcomes. However, despite this, a significant proportion of patients fail to respond to immunotherapy, especially those with less immunoresponsive cancer types, and there remains a need for new treatment strategies. The virtual Immunotherapy Bridge (December 1st–2nd, 2021), organized by the Fondazione Melanoma Onlus, Naples, Italy in collaboration with the Society for Immunotherapy of Cancer addressed several areas of current research in immunotherapy, including lessons learned from cell therapies, drivers of immune response, and trends in immunotherapy across different cancers, and these are summarised here.
KW - Biomarkers
KW - Checkpoint inhibitors
KW - Combination therapy
KW - Immunotherapy
KW - Tumor microenvironment
KW - Vaccine
UR - http://www.scopus.com/inward/record.url?scp=85131465855&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85131465855&partnerID=8YFLogxK
U2 - 10.1186/s12967-022-03471-y
DO - 10.1186/s12967-022-03471-y
M3 - Article
C2 - 35672823
AN - SCOPUS:85131465855
SN - 1479-5876
VL - 20
JO - Journal of translational medicine
JF - Journal of translational medicine
IS - 1
M1 - 257
ER -